HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Jumps Out Of The Red In Q4 With Net Income Of $46.2 Mil.

This article was originally published in The Rose Sheet

Executive Summary

Revlon's efforts to improve its capital structure and grow operating income paid off in the fourth quarter, leading the firm's return to profitability for the first quarter in six years, the company announced during a March 8 analyst call

You may also be interested in...



Almay Intensifies Color Offerings With Eye-Enhancing Products

Almay will support the launch of Intense i-Color with print and television ads breaking in January, the Revlon division said. The line will have the largest advertising budget of any Almay product next year, the firm added

Revlon Unveils Plan To Cut Debt As Q4 And Year End Loss Narrows

Revlon has developed agreements with Fidelity Management and Research and MacAndrews & Forbes, the firm's principal shareholder owned by Chairman Ronald Perelman, that will reduce the color cosmetics marketer's debt by $930 mil., or approximately 50%, by March 31, 2006, the company reported Feb. 12

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel